DrugPatentWatch Database Preview
N - Biologic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Company Disclosures: US Patents for n
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | University of Iowa Research Foundation (Oakdale, IA) | 2009-12-01 | RX | company | |
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | University of Iowa Research Foundation (Iowa City, IA) | 2005-01-30 | RX | company | |
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | Fred Hutchinson Cancer Research Center (Seattle, WA) | 2015-03-24 | RX | company | |
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | company | |
| Biogen Idec | TYSABRI | natalizumab | VIAL; SINGLE-USE | 125104 | 001 | 2004-11-23 | Start Trial | Elan Pharmaceuticals, Inc. (South San Francisco, CA) | 2017-03-07 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for n
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC) | 2035-06-26 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Biodesix, Inc. (Boulder, CO) | 2035-07-13 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN) | 2034-10-30 | RX | search | |
| Bristol Myers Squibb | OPDIVO | nivolumab | INJECTABLE;INJECTION | 125527 | 001 | 2015-03-04 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2032-08-30 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
